Category: <span>PD-L1</span>

Category: PD-L1

Dako North America Inc., Dr. Richard Pazdur, Dr. Roger M. Perlmutter, FDA, Immunotherapy, Keytruda, Merck, mesothelioma cancer, Mesothelioma News, Non-small cell lung cancer, NSCLC, PD-L1, U.S. Food and Drug Administration

FDA-Approved Keytruda Treatment Could Help Mesothelioma Patients

 

Recently, the FDA approved Merck immunotherapy drug Keytruda for treatment in non-small cell lung cancer and is bringing hope to mesothelioma patients.